Colistin dosing and nephrotoxicity in a large community teaching hospital.
about
Renal and neurological side effects of colistin in critically ill patientsRisk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyCarbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi ArabiaPopulation pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsColistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicityIncidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsApplication of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killThe combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelDefining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteriaMulticenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolThe risk factors of colistin methanesulfonate associated nephrotoxicity.Evaluation of Risk Factors for Intravenous Colistin Use-related NephrotoxicityCell cycle arrest in a model of colistin nephrotoxicity.Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Colistin: an update on the antibiotic of the 21st century.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.Emergent renal dysfunction with colistin pharmacotherapy.Colistin: understanding and applying recent pharmacokinetic advances.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.Adverse reactions associated with systemic polymyxin therapy.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.A review on colistin nephrotoxicity.Colistin: efficacy and safety in different populations.Strategies for the safe use of colistin.The safety of polymyxin antibiotics.Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.Use of Colistin in a Neonatal Intensive Care Unit: A Cohort Study of 65 PatientsRecent advances and perspectives in the design and development of polymyxins.Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Is there really no benefit to combination therapy with colistin?
P2860
Q27499294-5216750D-9F01-448E-B662-D5386B656091Q33751736-B468969C-0FB4-4CF7-B9AB-CBC0BAC1676DQ34437229-D7E44588-67EC-4843-B014-66EA6ABA06CCQ34955582-48677FF6-7535-41F7-BC0F-119E794008FEQ34994417-E7CC9C85-1851-4A5A-8447-AC08B9E48750Q35065863-7D6FC468-8EAA-4A7A-A349-17DC9EAD55B2Q35432770-D60F3B23-812D-40BB-B31F-333EEF7C49A9Q35607925-557601BB-EF36-40E6-994D-C50A6AD406E2Q35941403-CF8F4BDF-F32C-4BAE-832A-818DBDA4BF73Q36171772-3C5397F9-F516-4C2F-A517-92B09B7AFD42Q36276852-5600EEAB-A34D-40F8-934E-3EBA690345DEQ36299428-E0EFB394-1779-48E4-A432-B170B760B984Q36730174-58C31290-9ED8-479B-81A0-FD46DBE05A04Q36818945-E9F90D06-3B72-466E-861D-DE2376A97038Q37041117-D14E8FBC-5C8E-4FCD-B644-C6E0FF2C6D8FQ37053617-162E0CDD-30AA-4B92-B374-CE6DBF4CAC81Q37234937-C1B24612-EBE7-4CF1-B202-E1BE1B27BBA8Q37729344-D2C19C4E-37F2-454A-99E8-BB400ED1CBF6Q37838126-FAE87BB5-7138-4668-99DD-D66F93876512Q37869910-30D43739-4313-451C-883D-F2FCB60B85FBQ38019839-CD79A43C-D538-4C51-B6B0-A0EE8CFF1033Q38048852-F79DB9C9-03BF-4DF9-997C-A29058724EE1Q38097120-BB9CC29F-FB0E-4DCA-AC50-D45334196C54Q38100749-2E643EF5-5CAD-4334-BCBE-D0D3529E9732Q38246001-79DC708E-5F9C-432B-90AB-8C93E311B229Q38247400-EC987F64-3A79-46CD-AA91-840CBAB1D18CQ38252561-2FC49DAB-B615-4615-A0FC-361F5132CD61Q38255373-6B5030CD-E791-475F-8729-485A46A561AFQ38262205-C86D5C28-7870-428E-AB77-47FDA320190CQ38501685-1E9A7CCC-D4E5-4B8E-BDB1-8D702843DCB7Q38514980-0F74E337-DB2E-44EF-835D-53C6D288430DQ38548658-ECA8DACE-2D8D-4E44-B451-B9C6BCFE0B24Q38586123-9EAACAD4-9721-4537-844E-79B99DC659B5Q38869608-2111DBA9-E88E-4015-9FF4-EA7F1E58C93CQ38992007-F5911DC2-57AB-4891-B613-A0921F8F4BC5Q39190865-45CCE892-22A2-40FE-AE9F-9AE7701D598CQ39204542-EC59A2AE-512E-4A2B-B766-9E5EB26D5560Q39236424-052563C6-983B-4085-BB98-0EE499B42180Q39333751-EEC25EA3-A9B2-450D-B4D1-9BB27D926AE9Q39347152-0F7C228A-7B36-4870-ABD2-EB01D678C192
P2860
Colistin dosing and nephrotoxicity in a large community teaching hospital.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@ast
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@en
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@nl
type
label
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@ast
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@en
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@nl
prefLabel
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@ast
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@en
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@nl
P2093
P2860
P356
P1476
Colistin dosing and nephrotoxicity in a large community teaching hospital.
@en
P2093
Amanda J Crawford
C Andrew Deryke
Mark R Wallace
Nizam Uddin
P2860
P304
P356
10.1128/AAC.01707-09
P407
P577
2010-07-26T00:00:00Z